An Overview of Ebola Virus - It's Pathogenesis, Treatment and Vaccination
Ebola virus disease (EVD) is previously known as Ebola hemorrhagic fever. It is a serious fatal illness to human. EVD is caused by the Ebola virus. The outbreak of Ebola virus began in the Republic of Guinea in February 2014.The 2014 West Africa outbreak is believed to be most severely recorded in medical history. Around 1440 cases with 826 deaths have been reported. But around 16,000 people survived in West Africa. A cellular protein acts as a receptor for Ebola virus and Marburg virus. TIM-1 acts as a receptor for Ebola virus which is a cellular protein. It is transmittable disease which occurs by the contact with the blood or body fluids of a person who was infected or died from EVD, contaminated objects like needles and infected animals or meat. Burial ceremonies in which mourners have direct contact with the body of the deceased person can also major role in transmission of Ebola. EVD has an incubation period of about 2 to 21 days, and the infection has an acute onset without any carrier status. At present, there is no particular type of treatment for EVD, so it is important to avoid infection exceeded 80%, modern medicine in public health measures have been taken to reduce the smack of EBD on individuals and communities. Treatment for Ebola virus involves early, truculent, supportive care with rehydration. Typical symptoms of Ebola virus disease include fever, diarrhea, nausea and vomiting for about 3-5 days and may lasts up to one week, abdominal pain. Upon increase in severity of the virus the patient may suffer from confusion, dehydration, and hypotension. These conditions eventually may lead to death. Ebola virus may be spread due to insufficient medical facilities, poor sanitation, unsafe burial practices. Ebola virus does not replicate through cell division. There is no definitive cure and management is mainly supportive ensuring adequate hydration and symptomatic treatment.
2. Diehl WE ,Lin AE ,Grubaugh ND et al. (2016); Ebola virus glycoprotein with increased infectivity dominated the 2013–2016 epidemic; Cell. ; 167(4); 1088-1098.e6
3. Houlihan CF ,McGowan CR ,Dicks S et al. (2017); Ebola exposure, illness experience, and Ebola antibody prevalence in international responders to the west African Ebola epidemic 2014–2016: a cross-sectional study; PLoS Med. ; 14(5); e1002300
4. Ouattara E ,Duvignaud A et al. (2017); Impact of the Ebola outbreak on Trypanosoma brucei gambiense infection medical activities in coastal Guinea, 2014–2015: a retrospective analysis from the Guinean national Human African Trypanosomiasis control program.; PLoS Negl Trop Dis; 11(11): e0006060
5. Sochas L ,Channon AA ,Nam S (2017); Counting indirect crisis-related deaths in the context of a low-resilience health system: the case of maternal and neonatal health during the Ebola epidemic in Sierra Leone; Health Policy Plan; 32(suppl_3); iii32-iii39